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ABSTRACT
The U.S. Food and Drug Administration holds authority over the regulation of
medical devices. To assure the safety of the public, medical devices are designated into
classes according to their risk of danger and intended use. The device must meet the
criteria of the assigned premarket submission to be legally marketed in the United States.
Section 513(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360c(g)) is a
request for information concerning the classification and regulation of a device. There is
an empty spot in the market for continuous monitoring of coagulation status. The
Coagulation Companion by MicroVide is a device designed to fluorescently quantify a
key enzyme involved in the coagulation cascade, plasmin, as a means of monitoring clot
formation and degradation in pediatric patients undergoing congenital heart surgery.
Through the submission of a 513(g) Request for Information, non-binding information on
the device’s generic device type, Class, pre-market submission, and product code would
apply to the Coagulation Companion.
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CHAPTER 1
INTRODUCTION
1.1 FDA and Devices
In 1938, the United States Congress passed the FD&C Act to provide the
government with authority over the safety and efficacy of food, drugs, and cosmetic
items. Enforcing product standards and regulatory requirements deterred mislabeled,
dangerous, and ineffective products from entering the market in 1976. The FDA’s control
was expanded to include the regulation of medical devices. The Center for Devices and
Radiological Health (CDRH) is responsible for assessing the safety and effectiveness of a
medical device prior to it entering the market and for continuing to monitor the device as
it is marketed. Devices are sorted into one of three classes determined by their potential
risk to the user and the depth of regulation required to determine that the product is both
safe and effective.
Section 513(g) of the FD&C Act governs requests “for information respecting the
Class in which a device has been classified or the requirements applicable to a device
under [the] Act.” (Food, Drug and Cosmetic Act, 1938). For a product to be considered a
“device”, it must meet the requirements as described in section 201(h) of the FD&C Act
(21 U.S.C. 321(h)). Based solely upon the information the requestor provides, the FDA
will respond with their non-binding advisement on the device’s possible classification,
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the type of premarket submission required to market the device, and other requirements
which may be applicable.
Often times, medical device manufacturers submit a 513(g) request to establish
the regulations that will precede the device’s approval for marketing. Low risk device
classes are subject to fewer controls which allows for a quick approval process. The
513(g) request serves as a tool to predict the regulations relevant to the device so that the
manufacturer has the option of altering the device before proceeding to a premarket
submission.
1.2 Formation of a Blood Clot
The coagulation cascade is the process by which a blood clot is formed once a
blood vessel is damaged. There are two pathways with both leading to the production of
fibrin which, forms the blood clot. Plasmin is an enzyme involved in the degradation of
fibrin. Once the need for clotting ceases, plasminogen is cleaved into its active form,
plasmin, to destroy fibrin (Medcaf & Keragala, 2021). Fibrinolysis is tightly regulated, so
high levels of plasmin reflect the need to restore normal blood flow (Napolitano &
Montuori, 2021). Monitoring the presence of active plasmin indicates the need to form or
degrade fibrin, indicating coagulation status.
1.3 The MicroVide Coagulation Companion
The Coagulation Companion is a device by MicroVide. The device functions
continuously by injecting the device’s plasmin substrate into the subcutaneous space of
the patient’s shoulder through a microdialysis catheter. The substrate is cleaved by active
plasmin which causes the substrate to fluoresce. The substrate flows back through the
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microdialysis needle and to the detector where the fluorescence is quantified. The device
provides continuous monitoring for the best estimates of the blood’s ability to form clots.
This 513(g) is being submitted for the Coagulation Companion in order to get the
FDA’s current views on the classification of the device and the regulatory requirements
in place for such a device. With the FDA’s regulatory guidance, the correct premarket
requirements can be met, and the submission can be filed to earn the Coagulation
Companion the ability to enter the market as a medical device legally marketed in the
United States.
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CHAPTER 2
THE U.S. FOOD AND DRUG ADMINISTRATION
2.1 The Pure Food and Drug Act
Though the federal government has been involved in the safety of agricultural
products since 1848, it was not until the 1906 Pure Food and Drugs Act that they engaged
in regulation of food and drugs (History, Art & Archives). The Act was constructed
following a wave of journalists revealing the shocking conditions in which foods were
being prepared for human consumption (FDA, 2019). The public outrage in response to
Upton Sinclair’s 1906 novel, The Jungle, an exposé of the foul conditions of the meatpacking industry, drove the U.S. Congress to propose legislation to counteract the
unsanitary food processing conditions (Fortin, 2016). The U.S. House of Representatives
passed the Act on June 29th of 1906, with 240 representatives voting in favor and 17
voting against (FDA, 2019). President Theodore Roosevelt signed the Act into law the
following day. “For preventing the manufacture, sale, or transportation of adulterated or
misbranded or poisonous or deleterious foods, drugs, medicines, and liquors, and for
regulating traffic therein, and for other purposes,” (Federal Food and Drugs Act, 1906).
The central focus of this law concerned the regulation of consumer-obtainable products
rather than the regulation of those which were upcoming and yet to reach the market
(Fortin, 2016). The Act eliminated many dangerous products from the market but was not
without a loophole (The Food and Drug Administration: The Continued History of Drug
Advertising, n.d.). In the 1911 United States v. Johnson Supreme Court case, it was ruled
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that the term “misbranded” only referred to false statements of identity and did not cover
statements as to curative effect (Holmes, 1911). Legal proceedings could only take place
if it was evident that the manufacturer’s intent was to defraud the customers, which made
it difficult to stop the sales of dangerous products.
2.2 The Federal Food, Drug and Cosmetic Act
In 1933, the Chief Education Officer, Ruth Lamb, and Chief Inspector, George Larrick,
of the FDA called attention to the insufficient regulation with an exhibit demonstrating 100
harmful or dishonest products which did not fall within jurisdiction of the FDA (FDA, 2018).

The public found the exhibit so disturbing that it was labelled the “American Chamber of
Horrors” (FDA, 2018). President Franklin Roosevelt signed the Federal Food, Drug, and
Cosmetic Act (FD&C Act) in 1938, solving many shortcomings of the 1906 Act (FDA,
2018). The 1938 Federal Food, Drug, and Cosmetic Act served to fortify the FDA’s
authority over product regulation. The FDA’s authority over foods and drugs was
expanded to include cosmetics and medical devices. (Office of the Commissioner, 2018)
For the first time, product regulations were placed prior to production decreasing the
likelihood of mislabeled or dangerous products reaching the market. The manufacturers
faced the threat of criminal charges should they fail to comply to the new standards. (Part
II: 1938, Food, Drug, Cosmetic Act, 2018) In 1976, the FD&C Act was amended to
introduce regulatory measures for medical devices to assure safety and effectiveness of
the products.
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CHAPTER 3
MEDICAL DEVICES UNDER THE FDA
3.1 Classes of Devices
Once a product is confirmed to meet the definition of device as described in
Section 201(h), the CDRH categorizes it into one of the three device classes. The device
classes are based on the extent of risk the device poses to the device user and the
regulation requirements to determine the product safe for marketing. In December of
2021, the CDRH reported that Class I contained 35% of medical devices, Class II
contained 53%, and Class III contained 9%. The remaining 3% were considered
Unclassified.
3.1.1 Class I
Class I consists of devices which pose minimal risk of harm. In this category,
there are devices such as manual stethoscopes and adhesive bandages. Generally, these
devices are simple in design. They are for external use and do not directly impact the
health of the user. Only general regulatory controls are relevant to these devices.
3.1.2 Class II
Devices with moderate risk are sorted into Class II. The devices present greater
potential danger than Class I, but less than that of Class III. A large focus of this Class is
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on monitoring systems such as apnea monitors and insulin. General regulatory controls
and, if available, special regulatory controls apply to Class II devices.
3.1.3 Class III
The highest risk devices are grouped into Class III. These are devices that are
purposed to support life, implanted into the body, or have severe risk of injury. Devices
such as heart valves and cardiac pacemakers are considered in Class III. Devices within
Class III must comply with general regulatory controls and have premarket approval,
though occasionally a premarket notification will be accepted in its place.
3.2 Regulatory Controls
3.2.1 Premarket Notification Exempt
Devices within Classes I or II may be exempt from the premarket notification
process. Section 510(k) of the FD&C Act states that the 510(k) exemption of a device is
limited to “the extent that the device has existing or reasonably foreseeable characteristics
of commercially distributed devices within that generic type”. A device must have the
same intended use and the same technological features of the generic device type to be
considered exempt. The devices themselves have very low risk of harm “to the extent that
misdiagnosis as a result of using the device would not be associated with high morbidity
or mortality,”. The FDA reported that 93% of Class I devices were with exemptions in
2021. General controls such as good manufacturing practices, establishment registration,
and device listing, apply to all devices, including those considered exempt from the
premarket notification process.
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Postamendement device are those which entered the market after the 1976
Amendments to the FD&C Act. Due to the rapid advancement of technology, most
developing devices claim substantial equivalence to the ones approved after the
amendment. Preamendment devices are those that entered commercial distribution prior
to May 28th of 1976 and have the same intended use. The Code of Federal Regulations
requires the device to not have been “significantly changed or modified” since that date
and to not have a PMA application published by the FDA. These devices are exempt
from the premarket notification process.
3.2.2 Premarket Notification
A premarket notification, more frequently referred to as a 510(k), seeks FDA
clearance of a medical device. It is the most common type of submission to demonstrate
product safety and effectiveness. 510(k) submissions frequently do not require clinical
data to support the device’s clearance. The majority of Class II devices and an occasional
Class I or Class III device are required to complete this type of submission.
The product must be compared to at least one device legally marketed in the
United States to claim substantial equivalence as described in Section 513(i)(1)(A) of the
FD&C Act. The FDA identifies a legally marketed medical device as eligible to claim
substantial equivalence as “a device that was legally marketed prior to May 28, 1976
(preamendments device), or a device which has been reclassified from Class III to Class
II or I, a device which has been found SE through the 510(k) process, or a device that was
granted marketing authorization via the De Novo classification process under section
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513(f)(2) of the FD&C Act that is not exempt from premarket notification requirements”.
These devices are termed “predicates”.
The definition of a valid substantially equivalent medical device, which may be
considered a predicate, is outlined in The Medical Device Amendments of 1976, 21
U.S.C. § 360c(i)(1) which states that if “the device has the same intended use as the
predicate device and … has the same technological characteristics as the predicate
device” or “has different technological characteristics and the information submitted that
the device is substantially equivalent to the predicate device contains information,
including appropriate clinical or scientific data if deemed necessary”. The supplementary
proof of equivalency is essential in establishing lack of deviation from the safety and
effectiveness already shown by the legally marketed device.
3.2.3 Premarket Approval
Premarket Approval, or PMA, is for devices where general controls and
premarket notifications were proven insufficient in proving safety and effectiveness. All
Class III devices require a PMA to gain FDA approval. As Class III is comprised of the
devices with the highest potential danger, the device’s review is significantly more
intense than the 510(k). Clinical data is required for this submission, usually involving
human clinical trials. Figure 3.1 presents the basic routes for device entry to the market.
3.2.4 De Novo
The De Novo classification is an alternative pathway for novel devices. The Code
of Federal Regulations identifies this route as a way to “establish an efficient, transparent,
and thorough process to facilitate De Novo classification into Class I or Class II devices
9

Figure 3.1 The Pathways for a Medical Device to Enter the Market.
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for which there is no legally marketed device on which to base a review of substantial
equivalence, and which meet the definition of Class I or Class II”. Though De Novo
devices are of low to moderate risk, Class III is the only classification allowed as the
FDA has not regulated anything similar enough to be considered substantially equivalent,
no matter the level of safety.
3.3 Device Safety
3.3.1 Postmarket Surveillance
Postmarket surveillance may be required to determine the long-term side effects
of a marketed medical device under Section 552 of the FD&C Act. A postmarket
surveillance plan outlines the methods a manufacturer intends to use for the ongoing
observation of marketed devices as described in 21 C.F.R. § 882.10. According to 21
U.S.C. § 360(l), Class II or III devices may be ordered to provide postmarket surveillance
if: the device’s failure would significantly impact the user’s health, is significantly used
by pediatric patients, is intended to be implanted in the human body for over a year, or is
intended to be a life-sustaining or life-supporting device used outside a device user
facility. The type of surveillance design is chosen to fit the device’s area of concern and
must be agreed upon by the manufacturer and the FDA. Under the FD&C Act, the FDA
may keep a device under postmarket surveillance for no longer than 36 months unless
agreed upon by the manufacturer.
3.3.2 Medical Device Reporting Program
To ensure that a legally marketed device continues to meet the FDA’s standards
of safety and effectiveness, the Medical Device Report (MDR) Program was formed. The
11

submission of reports by manufacturers, device user facilities, and importers is
mandatory when a device suspected to have contributed to user injury is identified as
stated in The Medical Device Reporting regulation. Though not mandatory, it is
encouraged that healthcare professionals and consumers submit voluntary reports if they
notice signs of a device potentially causing harm. These reports serve as records for the
number of adverse events surrounding a particular device. A device with a large number
of reports is more likely to be directly related to injury compared to a device with few
reports.
3.3.3 Recalls
Recalls are used to remove or correct consumer products that do not meet the
standards set by the FDA. A recall, as defined by 21 C.F.R. § 7, is “a voluntary action
that takes place because manufacturers and distributors carry out their responsibility to
protect the public health and well-being from products that present a risk of injury or
gross deception or are otherwise defective”. The FDA offers guidance on policies and
procedures concerning recalls to assist manufacturers. If a manufacturer fails to
voluntarily conduct a recall, the FDA may exercise their right to issue a recall under 21
C.F.R. § 810 Medical Device Recall Authority. For manufacturers to proceed with the
removal or correction of a medical device, the FDA must determine the product to not
meet their standards. A report on medical device recalls is prepared weekly by the FDA
and is available to the public.
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CHAPTER 4
SECTION 513(G) REQUEST FOR INFORMATION
4.1 The 513(g) Submission
4.1.1 Scope of Information
The 513(g) is submitted when a manufacturer is interested in determining the
device status and the regulations that would be placed upon a product. The information
provided in the response allows the manufacturer to determine if they should move
forward with the premarket submission, modify the device to achieve the preferred
designation, or to discard the product if it is not a device. If there is no obvious
classification code to fit the product, predicting the device Class is difficult. The 513(g)
submission would be the most successful way to predict the device Class without
knowing the code.
Section 513(g) only manages information concerning the classification and
regulation of medical devices. The agency does review information concerning
substantial equivalence to existing devices or any proof of safety and effectiveness.
Substantial equivalence, safety, and effectiveness of a product are not considered within
the request. Appropriate testing, whether it be clinical, nonclinical, or animal, will not be
discussed.
All information provided is non-binding and to be used as suggestions.
Information regarding performance data and requests for medical device reclassification
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are not handled in this submission. The FDA reader is restricted in product information
and must base their assessment on only the information provided in the submission.
4.1.3 Content within the Submission
The 513(g) Request is the formal approach for obtaining information about the
classification and regulation of a medical device. The FDA’s reader relies solely on the
information provided within the submission to form their opinion on the product. A
descriptive mechanism of action and a highly detailed device description clarifies the
agent’s overall understanding of the device.
The information required to meet the 513(g) Request requirements are separated
into four sections: a cover letter, the device description, the device’s intended use, and
any proposed labeling materials. The FDA offers a guidance document for industry and
staff titled “FDA and Industry Procedures for Section 513(g) Requests for Information
under the Federal Food, Drug and Cosmetic Act” containing the procedures surrounding
the Submission of a 513(g) Request for Information. The required contents are described
as follows:
Your cover letter should include: the date of the request, the name of the device,
any specific question(s) concerning the Class in which a device has been classified and/or
the regulatory requirements applicable to a device, the requestor’s name, address,
telephone number, fax number, and email address, and the 513(g) requestor’s signature.
As applicable, the description of the device should include: a list of materials and
components used in/with the device, photographs, engineering drawings, and/or samples
of the device, a summary of the device’s operational principles, a description of the type
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and amount of energy to be used or delivered by the device, and a description of similar
devices in commercial distribution in the United States, if available.
Device Uses include the following information: the disease or condition with
respect to how the device is to be used, prescription versus over-the-counter use, part of
the body or type of tissue applied to or interacted with, frequency of use, physiological
purpose, patient population; and any other labeling information related to the patient use
of the device.
Ifeanyi Uwemedimo, a device determination policy analyst within the Office of
Regulatory Programs, recommends that the device description is kept clear and brief. The
information should be focused on providing an explanation as to how the device
accomplishes its intended use. The addition of pictures and schematics may assist in
conveying the device’s mechanisms to the FDA reader. Labelling claims are those made
beyond the intended function of the device and can help in determining the medical
device’s risk and if performance data must be included to support the claim.
One electronic copy of the submission or one paper copy is sent to the Centers for
Devices and Radiological Health. There is a user fee of $5,061 required before the
agency begins to review the 513(g) submission. The price is reduced to $2,530 for “Small
Businesses” whose gross annual sales are under $100 million for the most recent tax year.
4.2 The Agency’s Response
513(g) submissions are confidential and will not be reported by the FDA. None of
the information provided in the request is an official decision and is only to be considered
advice. To determine a new device’s Class, the FDA reviewer will consult the relevant
databases containing product codes, 510(k)s, and De Novo submissions to seek similar
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devices which have been regulated by the FDA. The technology and intended use
described within the submission will be referred to when considering regulations and
seeking precedents set by approved medical devices. In some cases, the lead reviewer
may consult an internal subject matter expert to better comprehend the product. A
product involved in many disciplines may require an extended period of time as more
research must be completed to form an adequate response. Typically, responses to the
513(g) submission are typically provided within 60 days of receipt. The Agency’s
response will take the form of a formal letter and will only be sent once an agreement is
reached between reviewers concerning the contents of the response.
If the product is considered to be a device as defined in section 210(h) of the
FD&C Act, it will be noted in the response. The device being either a preamendment or
postamendment device type will be address. The response will identify a classification
code and classify the device in either: Class I or II subject to the 510(k) requirement;
Class I or II exempt from the 510(k) requirement; or Class III subject to the 510(k) or
PMA requirements. Directions towards the appropriate premarket guidance document
will be provided. Additional information on extra requirements, such as the regulation of
radiation-emitting devices, will be discussed.
Alternatively, the product may be determined to not be a device or that it is a
combination product. If the product is not a device, it will be noted in the response. If it is
seen as a product regulated by the FDA, the response will direct the submitter to the
correct department. A combination device is one which could fall under the jurisdiction
of multiple Centers. For this determination, directions will be given for contacting the
Office of Combination Products.
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CHAPTER 5
THE COAGULATION COMPANION
5.1 The Coagulation Cascade and Plasmin
The National Institutes of Health defines a blood clot as “A mass of blood that
forms when blood platelets, proteins, and cells stick together,”. Coagulation is the process
by which a blood clot is formed. As the pathway features downstream activation, the term
“cascade” has been applied. The factors involved in coagulation are proteins which
exhibit enzymatic activity once activated. Thirteen factors are involved in the cascade:
factor I (fibrinogen), factor II (prothrombin), factor III (tissue factor), factor IV (ionized
calcium), factor V (proaccelerin), factor VI (unassigned), factor VII (proconvertin), factor
VIII (antihemophilic factor), factor IX (plasma thromboplastin component), factor X
(Stuart-Prower factor), factor XI (plasma thromboplastin antecedent), factor XII
(Hageman factor), and factor XIII (fibrin-stabilizing factor) (Chaudhry et al., 2021). The
pathways flow with a domino effect with each factor activating the next. The intrinsic
and extrinsic pathways merge into the common pathway with factor X, the only factor
shared by the pathways as seen in figure 5.1.
The intrinsic pathway utilizes factors I, II, IX, X, XI, and XII. Exposure to
negatively charged artificial surfaces, such as glass, fibers, and some plastics, activate
factor XII to trigger the intrinsic pathway. The pathway begins with the activated factor
XII activating factor XI. The active form of factor XI, along with calcium ions, activates
factor IX. Active factor IX congregates with factor VII on membrane surfaces, stabilized
17
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Figure 5.1 The Coagulation Cascade. The processes of forming a blood clot through the extrinsic and intrinsic pathways.

by calcium ions. The complex binds to and activates factor X and enters the common
pathway. The extrinsic pathway utilizes factors I, II, IV, and X. It is triggered by the
contact of factor VII with a membrane protein called tissue factor that is released by
when the cells that line the blood vessels undergo damage. Active factor VII activates
factor X and the common pathway is entered.
The common pathway utilizes Factors I, II, V, VII, and X. The pathway begins
with the activation of factor X either intrinsically with factor VII and active factor IX or
extrinsically with factor VII, tissue factor, and calcium. Active factor X along with factor
V cleave prothrombin into thrombin. The thrombin activates factors XI, V, VIII, and XIII
as well as cleaving fibrinogen into fibrin. The fibrin congregates into fibers and is
stabilized by factor XII to form netting. The buildup of this structure eventually forms a
thrombus (clot).
The major negative regulation fibrinolytic mechanism of the coagulation cascade
is through the enzyme plasmin (McGilvray, 2001). Plasminogen is cleaved to its active
form, plasmin, by tissue-type plasminogen activator or urokinase plasminogen activator
(Baker, 2020). Once there is no longer a need for clotting, Plasmin is active in fibrin
degradation. Plasmin levels increase as a response to excessive blood clotting which may
be used to indicate coagulation status.
5.2 The Unmet Need
Anticoagulants are medications used to restrict the blood’s ability to form clots.
They are commonly prescribed to prevent post-operative blood clots from forming. If an
inappropriate quantity of anticoagulant is introduced, potentially fatal bleeding may occur
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preoperatively, hemoglobin or complete blood counts, screening tests for bleeding
disorders, and testing for patients receiving anticoagulants may be used to predict the risk
of bleeding but are not infallible. In a 2019 study, 215 patients undergoing elective
cardiac surgery were studied and found that post-operative bleeding complications were
observed in 26.5% of the cases (Klingele et al., 2019). Hemostasis management is
specifically difficult in pediatric patients as procoagulation factors and anticoagulation
factors differ in levels, characteristics, and interactions from those in adults (Achey et al.,
2020). The lower quantity of blood in babies and young children due to small size
contributes to the severe nature of any blood loss.
The medical device market lacks a device which is capable of continuous
monitoring of blood coagulation. Current options for coagulation monitoring are static
and slow. Successful monitoring of factors indicating coagulation status can lead to a
lower volume of blood lost post-operatively and a lower mortality rate.
5.3 The Section 513(g) Request Submission
5.3.1 Cover Letter
Along with the submitter’s contact information on the cover letter of the 513(g),
specific questions were listed as follows:
1. Would this device be considered a combination device due to the plasmin
substrate?
2. What classification regulation applies to this device?
3. What Class of device within the generic device type applies to this device?
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4. Is there a required pre-market submission required prior to marketing for this
device?
5. Are there other FDA requirements which apply to this device type?
6. What product code is assigned to the Coagulation Companion?
5.3.2 Device Description
The Coagulation Companion (figure 5.1) is a continuous flow and detection
system that monitors the enzymatic activity of plasmin, a key indicator of coagulation
state. It is intended to help prevent post-operative blood loss in pediatric patients
undergoing cardiac surgery for congenital heart repairs. The Coagulation Companion is a
composite device containing:
•

Syringe Pump

•

Flow Through Optical Cell

•

PMT Detection System

•

Integrated Touchscreen

Additional components are sterile and disposable items that include:
•

Syringe (2.5 mL)

•

Plasmin substrate (6 µM)

•

Polyetheretherketone (PEEK) tubing (0.65 mm OD x 0.12 mm ID, 1 meter)

•

Microdialysis catheter (4 mm membrane length, 0.5 mm membrane diameter)

Figure 5.3 demonstrates the path in which the components are assembled. The
dotted box indicates the components contained within the device while the other
components are disposable. Figure 5.4 shows a kit representing the disposable items.
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Figure 5.2 External View. The front of the Coagulation Companion has the openings “IN” for
substrates entering the detection system and “OUT” for the waste.
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Figure 5.3 The Coagulation Companion as Assembled. The device components are
indicated by the box.
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Figure 5.4 A Kit of Disposable Items. Included are (A) a 2.5 mL sterile syringe, (B) a
microdialysis catheter with PEEK tubing, and (C) plasmin substrate.
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The Coagulation Companion is a consolidated device with the syringe pump
(Figure 5.5) and detection system defined by a single unit (Figure 5.6). A 2.5 mL sterile
syringe containing the plasmin substrate is located within the syringe pump.
The plasmin substrate is GMP-grade D-Ala-Leu-Lys-7-amido-4-methylcoumarin,
CAS No.: 104881-72-3, from BOC Sciences. Each 100 mL vial holds approximately 23.9
mg of the plasmin substrate. It is reconstituted in the hospital’s pharmacy prior to use
with 100 mL normal saline followed by two 1:10 dilutions. Ultimately, the concentration
is 6 µM. The plasmin substrate uses a LED light source and has an excitation wavelength
of 360 nm and an emission wavelength of 460 nm. The If the Coagulation Companion is
used for its maximum amount of time, three hours, a total of 3.16 ug of the plasmin
substrate will be administered.
The syringe pump infuses the substrate at a pre-calibrated flow rate, 6 µL/minute,
into the interstitial space. The substrate flows through the PEEK tubing, through the inlet
tubing of the microdialysis catheter (Figure 5.7) which is placed subdermally in the
shoulder region. The plasmin substrate is infused and quickly equilibrates with the
interstitial fluid. The substrate moves from high to low concentrations forming a
concentration gradient. The syringe pump continuously forces substrate into the
interstitial fluid. This high concentration drives the flow of the processed substrate
through the outlet tubing of the microdialysis catheter. The plasmin substrate flows
through the PEEK tubing and into the 10 µL cuvette housed within the PMT Detection
System (Figure 5.8). The substrate within the cuvette is subjected to a 380-nm LED and
produces a fluorescent signal that is amplified in the PMT. The fluorescence is digitally
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Figure 5.5 The (A) Syringe Pump with a (B) 2.5 mL Syringe.

Figure 5.6 An Internal View of the Coagulation Companion. (A) Syringe Pump, (B)
Syringe Pump Motor, and (C) PMT Detection System.
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Figure 5.7 A Labelled Microdialysis Catheter.
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Figure 5.8 The PMT Detection System. (A) The methylcoumarin emission bandpass filter has an excitation of
435 nm and a bandwidth of 40 nm (B) The rhodamine emission bandpass filter has an excitation of 543 nm and
bandwidth of 22 nm (C) The dichroic filter (D) The Methylcoumarin detector for plasmin (E) The Rhodamine
detector for kallikrein (F) The short-pass filter only transmits wavelengths below 650 nm (G) Dielectric turning
prism mirror (H) Achromatic lens (I) Flow Cell (J) Rhodamine excitation bandpass filter (K) Methylcoumarin
excitation bandpass filter.

displayed on the 7-inch Raspberry Pi integrated touchscreen that can be used in the
operating room.
The power supply of the Coagulation Companion uses a 12-volt adapter to
regulate output voltage. This power supply provides an output range of 11-13 volts with
output currents ranging from 1.36-1.15 A. The maximum output power is 15 watts.
5.3.3 Comparison with Similar Devices
TEG 6s Hemostasis System by Haemonetics (haemonetics.com) is a Class II
device with the same intended use as the Coagulation Companion. The TEG 6s is
intended to provide semi-quantitative indications of the hemostasis state of a venous
blood sample for coagulation studies. It is comprised of the TEG Hemostasis analyzer
and disposable TEG 6s Assay Cartridges. The system measures and records kinetic
changes in a sample of 3.2% citrated whole blood as clotting occurs.
The TEG 6s Citrated Assay Cartridges contain three independent citrated assays.
Clotting time, maximum clot strength, and fibrolysis after 30 minutes of reaching
maximum clot strength are the variables of interest. The data is recorded using changes in
physical clot elasticity.
The CMA Cerebral Tissue Monitoring System by CMA Microdialysis AB
(mdialysis.com) is a Class II device with technology comparable to the Coagulation
Companion. It is intended to monitor the perfusion status of cerebral tissue local to
catheter placement. The components of the system include the CMA 70 Brain
Microdialysis Catheters, CMA 106 Pump and Syringe, and CMA 600 Microdialysis
Analyzer and software.
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This system monitors biomarkers of ischemia in the brain. The parameters are
glucose, lactate, and pyruvate levels. The principles of “microdialysis” are utilized by the
system and resulting samples are collected in microvials and analyzed and displayed as
trend curves. It is to be used by patients 18+ in cases where ischemia or hypoxia is a
concern.
The microdialysis catheter utilized by the Coagulation Companion is from the
brand CMA Microdialysis AB. The Coagulation Companion’s catheter placement is less
invasive as it uses shoulder tissue rather than brain tissue. A comparison of the
Coagulation Companion to the similar devices may be seen in table 5.1.
Indocyanine Green is a fluorescent medical dye that has been approved for
commercial use since 1959. It is a cyanine dye used in determining cardiac output,
hepatic function, liver blood flow, and ophthalmic angiography. A significantly higher
quantity of Indocyanine Green is injected into the body compared to the Coagulation
Companion’s plasmin substrate. The comparison between Indocyanine Green dye and
plasmin substrate can be seen in table 5.2.
5.3.3 Intended Use
The Coagulation Companion is to be used to prevent post-operative blood loss.
Use is by prescription only. The microdialysis catheter is placed under the skin in
subcutaneous tissue and infuses a fluorescent substrate which quickly equilibrates with
the interstitial space. There is no contact between the plasmin substrate and the blood
stream. The returning fluid contains processed plasmin substrate. This is a single-use only
product. The duration of use is the intraoperative and postoperative period with the
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expectation of not to exceed 3 hours. The Coagulation Companion is intended to
continuously monitor a key enzyme that indicates coagulation and clot degradation
capabilities to prevent post-operative blood loss. The Coagulation Companion is to be
used by pediatric patients, up to 21 years of age, undergoing congenital heart surgery.
Approximately 40,000 children undergo congenital heart surgery in the United States
each year.
5.3.4 Proposed Labeling
There is no proposed labeling for the Coagulation Companion.
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Table 5.1 Device Comparison of Similar (green) and Unique (blue) Device Features.

Device

Coagulation
Companion

TEG 6s Hemostasis
System

CMA Cerebral
Tissue Monitoring
System

Manufacturer

MicroVide

Haemonetics
Corporation

CMA/Microdialysis
AB

Device Usage

Clinical Application

To monitor
coagulation state

To monitor
coagulation state

To monitor trends
in parameters
indicating the
perfusion status of
cerebral tissue

Parameters
Measured

Plasmin activity

Clotting time, clot
lysis, clot strength,
fibrogen contribution

Intracranial
glucose, lactate,
and pyruvate levels

Monitoring Style

Continuous

Stagnant

Stagnant

Patient Population
Age

Pediatrics

Adults 18+

Adults 18+

Diagnostic Use

Monitoring only

Monitoring only

Monitoring only

Device Description
Pathway Order:
Syringe
Same order
pump
• Microdialysis
Catheter
• Detector
Microdialysis
Subcutaneous tissue
Catheter Placement
•

Detector

Optical (PMT)
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Different components

Same order

No microdialysis
catheter

Cerebral tissue

Clot viscosity

Optical (Single
Beam Filter
Photometer)

Table 5.2 Comparison between Indocyanine Green to the Plasmin Substrate
Device

Clinical
Application

Indocyanine Green

Plasmin Substrate

For determining cardiac output,
hepatic function, and liver blood flow

For monitoring enzymatic activity
related to coagulation status

For ophthalmic angiography
Infusion
Method
Quantity
infused
after 3
hours

Intravenous

Subcutaneously

5.4 mg

3.16 ug
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CHAPTER 6
CONCLUSION
The U.S. Food and Drug Administration passed the Pure Food and Drug Act and
the Federal Food, Drug and Cosmetic Act to regulate various products, including medical
devices, to assure public safety. The FDA classifies medical devices into classes based on
their potential user harm and the methods to use them. Each Class is subject to a different
level of regulation, the highest risk products requiring the most proof of safety. Devices
can continue to be monitored after marketing and can be subject to recalls if adverse
events are reported. Section 513(g) of the U.S. FDC Act allows a manufacturer to submit
a request for non-binding information regarding a device’s classification and regulation.
The submission of a 513(g) is useful in predicting the device Class the product would be
placed in and what type of premarket submission would be required prior to entry into the
U.S. market. The Coagulation Companion is a device which would fill the medical device
market’s need for a way to continuously monitor coagulation in pediatric patients to
prevent post-operative bleeding. By including detailed information on the device’s
description and intended use in the 513(g) submission, the FDA’s reader will be able to
provide the most accurate response to the request.
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